AI assistant
CONTROL BIONICS LIMITED — Investor Presentation 2024
Nov 7, 2024
64611_rns_2024-11-07_c7453def-b74b-4a78-8898-0bb7d1389fe2.pdf
Investor Presentation
Open in viewerOpens in your device viewer
==> picture [177 x 63] intentionally omitted <==
8 November 2024
CONTROL BIONICS CEO to Present at Coffee Microcaps Morning Meeting
Control Bionics Ltd ( ASX: CBL ) ("Control Bionics" or "CBL") is pleased to announce that its CEO and Managing Director will be speaking at the Coffee Microcaps Morning Meeting scheduled for Friday, 8 November 2024. Mr Steele is scheduled to speak at 9.30am.
This virtual event offers an opportunity for all interested parties to gain insight into Control Bionics' recent advancements and strategic direction. Registration for the event is now open, and those interested can sign up via the following link: Coffee Microcaps Registration https://us02web.zoom.us/webinar/register/WN_BqWDGkk_RCGUOJIXwQ4rNw#/registration
.
This announcement is authorised by CBL CEO Jeremy Steele.
About Control Bionics:
Control Bionics is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses such as Motor Neurone Disease (MND) and Amyotrophic Lateral Sclerosis (ALS). Our core patented NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as EMG (Electromyography) output. This output is then sent wirelessly via the NeuroNode to a personal computer, enabling speech and other computer controlled functions like email and texting. Our technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse, and the NeuroNode acts as like the mouse button. Control Bionics is the only such product to harness three modalities – touch, eye and NeuroNode control – which combined yield unique benefits in terms of the ability of patients to express themselves with significantly faster speed and less fatigue.
Control Bionics recently extended its offering to mobility with the launch of DROVE – the autonomous wheelchair module. DROVE allows powered users the independence to operate their wheelchairs in their own homes for the first time. DROVE recently got approved by the TGA as a Class I medical device.
Control Bionics is currently commercialising its most recent advancement in its technology, the NeuroStrip ® . This wearable, miniaturised EMG device provides the business with the opportunity to enter new markets such as health diagnostics, sports performance and rehabilitation to name only a few potential markets.
Control Bionics operates in North America, Australia, Singapore and Japan.
Control Bionics Limited
Registered Office: Level 4, 11-13 Pearson Street, Cremorne, Vic., 3121 T: +61 3 9897 3576 W: www.controlbionics.com
ABN: 45 115 465 462
==> picture [177 x 63] intentionally omitted <==
Investors and Media
Jeremy Steele – CEO and Managing Director [email protected]
Brett Crowley - Company Secretary [email protected]
Investor Relations:
Joe Durak Executive Director & Founder Lynx Advisors [email protected] +61 414 465 582
Control Bionics Limited Registered Office: Level 4, 11-13 Pearson St, Cremorne, Victoria 3121, Australia T: +61 3 9897 3576 W: www.controlbionics.com ABN: 45 115 465 462
For further information visit the website: https://www.controlbionics.com/
Control Bionics Limited
Registered Office: Level 4, 11-13 Pearson Street, Cremorne, Vic., 3121 T: +61 3 9897 3576 W: www.controlbionics.com
ABN: 45 115 465 462